Ｏｂｊｅｃｔｉｖｅ　To investigate the efficacy of combination of morphine sulfate controlled-release tablet and buprenorphine sublingual tablet in patients with moderate to severe cancer pain， and explore effective analgesic therapies for advanced cancer pain patients.　Methods　One hundred and fifty patients with advanced cancer pain whose visual analog scale （VAS） scores were greater than 3 points and VAS scores were still greater than 3 points after treated with controlled-release tablet of morphine alone were randomly divided into two groups（n=75）： controlled-release morphine tablet alone group（M group） and conbination use of controlled-release morphine tablet with buprenorphine tablet group （MB group）. Analgesic effect， adverse reactions， living quality and patient's satisfaction were compared.　Results　Compared with single usage of controlled?蛳release tablet of morphine， the analgesic effect of combined therapy was significant， VAS score was significantly reduced（M group/MB group： M 26/10， S 4/0）（P＜0.05）. Nausea， vomiting and other adverse reactions decreased significantly（M group/MB group： nausea and vomiting 12/2， drowsiness 4/2， respiratory depression 9/4， dysuria 8/3， constipation 8/4）（P＜0.05）. Patient's satisfaction（M group/MB group： very satisfaction 10/14， satisfaction 36/47）（P＜0.05） and living quality［M group/MB group： sleep（5.5±1.2）/（4.6±0.7）， Mood（5.4±0.5）/（4.6±1.2）， Daily activities（5.1±0.4）/（4.9±0.5）， Social activities（5.5±0.4）/（4.8±1.6）］ were significantly improved（P＜0.05）.　Conclusions　The joint application of morphine sulfate controlled-release tablet and buprenorphine sublingual tablet was effective for advanced cancer pain. It can improve the potency of analgesia， reduce the incidence of adverse effects and improve the living quality of patients.